In this issue:
No increased risk of infections with long-term dupilumab
Discordant patient-physician views of paediatric AD disease control in Japan
AD does not impair academic performance in adolescents
Standardised definitions for AD disease states from the International Eczema Council
BROAD finds narrowband UVB more tolerable than broadband
Nemolizumab safe and efficacious for AD
Could acupoint autohemotherapy be beneficial for patients with AD?
Real-world dupilumab is effective in very young children with severe AD
Updated severity bands for AD outcome measures and the first bands for sleep loss
NOS2/CCL27-based molecular test accurately differentiates eczema from psoriasis
Please login below to download this issue (PDF)